Lexaria Bioscience (LEXX) News Today $0.95 +0.08 (+8.68%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.93 -0.01 (-1.32%) As of 07/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period LEXX - Lexaria Bioscience Corp Dividends - MorningstarJuly 12, 2025 | morningstar.comMLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Bioscience begins dosing for GLP-1 study #5April 3, 2025 | markets.businessinsider.comLexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | finanznachrichten.deLexaria Bioscience Corp.: Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-ArmFebruary 24, 2025 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Granted Two New DehydraTECH Patents for Treatment of EpilepsyFebruary 11, 2025 | finanznachrichten.deLexaria secures new patents for epilepsy treatment techFebruary 11, 2025 | msn.comLexaria Bioscience granted two new DehydraTECH patentsFebruary 11, 2025 | markets.businessinsider.comLexaria Bioscience Corp.: Lexaria Biodistribution Study For DehydraTECH GLP-1 is UnderwayFebruary 6, 2025 | finanznachrichten.deLexaria begins biodistribution study for DehydraTECH GLP-1February 6, 2025 | markets.businessinsider.comLexaria Bioscience provides update on ongoing human study GLP-1-H24-4February 5, 2025 | markets.businessinsider.comLexaria Bioscience Corp.: Lexaria Updates its Ongoing Human Study GLP-1-H24-4February 5, 2025 | finanznachrichten.deLEXX: IRB Approval Clears Way for GLP-1 Study #5January 28, 2025 | msn.comLexaria Bioscience stock target cut to $7 at H.C. WainwrightJanuary 24, 2025 | msn.comLexaria Bioscience forms Scientific Advisory BoardDecember 18, 2024 | markets.businessinsider.comLexaria Bioscience Corp. (NASDAQ:LEXX) CEO Acquires $51,134.72 in StockDecember 4, 2024 | insidertrades.comLexaria Bioscience’s Promising Developments and Ethics Board Approval Boost Buy RatingNovember 25, 2024 | markets.businessinsider.comLexaria Bioscience completes dosing for GLP-1 human pilot study #3November 25, 2024 | markets.businessinsider.comALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal StudyNovember 21, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight LossNovember 13, 2024 | finanznachrichten.deLexaria Bioscience provides GLP-1 industry updateNovember 8, 2024 | markets.businessinsider.comTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 13, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Shares Letter from Outgoing CEOSeptember 10, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) LiraglutideSeptember 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical SettingSeptember 5, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 31, 2024 | theglobeandmail.comHempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 29, 2024 | msn.comLexaria Bioscience Corp.: First Results from Lexaria's Second GLP-1 Human Pilot StudyAugust 28, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Announces Positive Interim Animal Study Results on DehydraTECH-CBD in Diabetes ControlAugust 22, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal StudyAugust 21, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Positive Results from Lexaria's Molecular Characterization StudyAugust 19, 2024 | finanznachrichten.deLexaria Bioscience (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Animal StudyAugust 7, 2024 | theglobeandmail.comLexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen HormoneAugust 4, 2024 | msn.comVanessa Carle Sells 2,567 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) StockAugust 3, 2024 | insidertrades.comLexaria Bioscience Corp. (NASDAQ:LEXX) Insider Vanessa Carle Sells 2,567 SharesAugust 1, 2024 | marketbeat.comInvenomic Capital Management LP Sells 258,716 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX)July 31, 2024 | marketbeat.comLexaria (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study DosingJuly 23, 2024 | theglobeandmail.comBuy Rating for Lexaria Bioscience on Promising DehydraTECH Efficacy and Solid FinancialsJuly 19, 2024 | markets.businessinsider.comBuy Rating on Lexaria Bioscience Fueled by Promising DehydraTECH Advances in Diabetes Drug DevelopmentJuly 19, 2024 | markets.businessinsider.comLexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, EpilepsyMay 23, 2024 | theglobeandmail.comLexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyMay 21, 2024 | finance.yahoo.comLexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal StudyMay 20, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing MarketsMay 17, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 17, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, IssuanceMay 10, 2024 | theglobeandmail.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address LEXX Media Mentions By Week LEXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LEXX News Sentiment▼-1.500.59▲Average Medical News Sentiment LEXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LEXX Articles This Week▼10▲LEXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CUE News Today HOWL News Today ADVM News Today PDSB News Today ANVS News Today ANL News Today GANX News Today NRXP News Today ATRA News Today KRON News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LEXX) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts